Claims for Patent: 10,265,402

Summary for Patent: 10,265,402

Title:	Absorption enhancers for drug administration
Abstract:	The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms. In various aspects, the invention provides compositions and methods for oral delivery in the form of a tablet.
Inventor(s):	Maggio; Edward T. (San Diego, CA)
Assignee:	Aegis Therapeutics, LLC (San Diego, CA)
Application Number:	15/942,110
Patent Claims:	1. An intranasal pharmaceutical composition comprising a suitable nontoxic, nonionic alkyl glycoside in combination with an anti-seizure agent, wherein the alkyl glycoside comprises dodecyl-.beta.-D maltoside at a concentration in the range of about 0.01% to 2.0%, and wherein the dodecyl-.beta.-D maltoside increases absorption and bioavailability of the compound in cerebrospinal fluid (CSF) of a subject. 2. The pharmaceutical composition of claim 1, in a format selected from the group consisting of a drop, a spray, an aerosol and a sustained-release format. 3. The pharmaceutical composition of claim 1, further comprising a mucosal delivery-enhancing agent selected from the group consisting of citric acid, sodium citrate, propylene glycol, glycerin, ascorbic acid, sodium metabisulfite, ethylenediaminetetraacetic acid (EDTA) disodium, benzalkonium chloride, sodium hydroxide, and combinations thereof. 4. An aqueous intranasal pharmaceutical composition comprising a suitable nontoxic, nonionic alkyl glycoside in combination with an anti-seizure agent, wherein the alkyl glycoside has a hydrophile-lipophile balance number in the range of about 10 to 20 and comprises dodecyl-.beta.-D maltoside, and wherein the dodecyl-.beta.-D maltoside increases absorption and bioavailability of the compound in cerebrospinal fluid (CSF) of a subject. 5. The pharmaceutical composition of claim 4, wherein the dodecyl-.beta.-D maltoside has a concentration in the range of about 0.01% to 1.0%. 6. The pharmaceutical composition of claim 4, in a format selected from the group consisting of a drop, a spray, an aerosol and a sustained-release format. 7. The pharmaceutical composition of claim 4, further comprising a mucosal delivery-enhancing agent selected from the group consisting of citric acid, sodium citrate, propylene glycol, glycerin, ascorbic acid, sodium metabisulfite, ethylenediaminetetraacetic acid (EDTA) disodium, benzalkonium chloride, sodium hydroxide, and combinations thereof.